Cemdisiran Withdrawn Phase 2 Trials for Atypical Hemolytic Uremic Syndrome (aHUS) Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03999840Eculizumab to Cemdisiran Switch in aHUS
NCT03303313A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome